For the success of a therapeutic antibody, diversity is key. It’s built into our approach.

We developed our CDRx® platform after witnessing many failed projects that didn’t consider the value of the ideal biophysical properties utilized by natural evolution. We saw many companies struggle with humanization because the humanized monoclonal antibody construct was limited to a set of human germline sequences.

We offer a unique, proprietary, in silico platform using a database of mature human frameworks, we will deliver a safe and effective humanized variant maintaining two-fold affinity.

By utilising a greater diversity of framework sequences, we increase the chances of successfully maintaining the binding function in the humanized format and also the chances of developing stable and robust antibodies that express well downstream. By creating a diverse pool of mature human frameworks we often improve the affinity or even specificity of the parental antibody.

By triaging frameworks for removal of those with sequence liabilities (incl. predicted T cell epitopes), we ensure that framework sequences are the best possible carriers for your CDRs.